COPLEY COPES WITH CONTAINMENT CRISIS; STOCK RECOVERS TWO POINTS IN APRIL
Copley Pharmaceutical appears to be turning the corner on Wall Street: the company posted a two-point gain in April to close at 26 after a 40% decline in value during the first three months of 1994 prompted by a Class I recall of albuterol solution. Investors warmed to the stock after Copley released test results showing that the contaminating organism in Copley's recalled albuterol was an environmental bacterium that rarely causes illness ("The Pink Sheet" April 4, T&G-13).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth